Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1143
- Registration Number
- NCT00409773
Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3148
- Registration Number
- NCT00408863
Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 716
- Registration Number
- NCT00405964
Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 547
- Registration Number
- NCT00406783
Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 350
- Registration Number
- NCT00403793
Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 62
- Registration Number
- NCT00400218
FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1099
- Registration Number
- NCT00398931
A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 650
- Registration Number
- NCT00398606
Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 41
- Registration Number
- NCT00398541
To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 58
- Registration Number
- NCT00398151
© Copyright 2024. All Rights Reserved by MedPath